As more practices adopt the COME HOME model, they are adapting it to fit their needs, explained Barbara McAneny, MD, chief medical officer of New Mexico Oncology Hematology Consultants. However, some practices may not have the resources to keep up with data collection requirements while ramping up clinical interventions.
As more practices adopt the COME HOME model, they are adapting it to fit their needs, explained Barbara McAneny, MD, chief medical officer of New Mexico Oncology Hematology Consultants. However, some practices may not have the resources to keep up with data collection requirements while ramping up clinical interventions.
Transcript (slightly modified)
How has the COME HOME model changed over the years?
At the beginning of COME HOME, it was 7 practices across the country. My practice, New Mexico Cancer Center, had done a lot of these policies and procedures because I take care of poor people, and having them be able to afford cancer care was obviously very important. As we moved it to the other practices, it had to adapt a little bit to work in each individual market. Some of the practices just did their Medicare patients; some like New Mexico Cancer Center expanded and did these processes for all of our patients.
It has changed a bit when it turned into the Oncology Care Model. The data collection requirements and the idea of superimposing the risk structure, this payment structure, on top of it is very different. When we did COME HOME, we added up all the costs of paying nurses to sit on the phone talking to patients as part of the triage pathway, the extra time it takes to have nurses and others educating patients as to how their disease would work and how to use our system to keep themselves healthy, and be able to have the opportunity costs of having expanded hours and having the ability to see patients the day they need to be seen.
When we added up all those costs, it came out more than the $160 per month that is the MEOS [Monthly Enhanced Oncology Services] payment, so I’m concerned that as it goes towards Medicare that practices will not have sufficient resources to really ramp up the clinical interventions that they need in their practices to really make it work. I also think that there’s a risk, like there was with the accountable care organizations, that all of the money paid in the MEOS payment will go towards the data collection to give back to Medicare, and that’s not really the intent.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children
March 19th 2025Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular atrophy (SMA) aged 2 to 17 years, who had previously been shut out of receiving gene therapy.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More